Compare, Analyse Cipla with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TEVA PHARMA (Israel) - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   TEVA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-19
TEVA PHARMA
Dec-13
CIPLA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6783,082-   
Low Rs4842,677-   
Sales per share (Unadj.) Rs198.21,768.9-  
Earnings per share (Unadj.) Rs18.5110.5-  
Cash flow per share (Unadj.) Rs35.0253.5-  
Dividends per share (Unadj.) Rs3.0096.73-  
Dividend yield (eoy) %0.53.4 15.4%  
Book value per share (Unadj.) Rs186.31,964.9-  
Shares outstanding (eoy) m805.70848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.91.6 180.0%   
Avg P/E ratio x31.426.1 120.3%  
P/CF ratio (eoy) x16.611.4 146.2%  
Price / Book Value ratio x3.11.5 212.7%  
Dividend payout %16.287.5 18.5%   
Avg Mkt Cap Rs m468,0312,442,036 19.2%   
No. of employees `00022.644.9 50.4%   
Total wages/salary Rs m28,5650-   
Avg. sales/employee Rs Th7,053.133,373.8 21.1%   
Avg. wages/employee Rs Th1,261.50-   
Avg. net profit/employee Rs Th659.12,084.8 31.6%   
INCOME DATA
Net Sales Rs m159,7101,499,986 10.6%  
Other income Rs m4,7660-   
Total revenues Rs m164,4751,499,986 11.0%   
Gross profit Rs m30,973410,772 7.5%  
Depreciation Rs m13,263121,245 10.9%   
Interest Rs m1,68429,462 5.7%   
Profit before tax Rs m20,791260,064 8.0%   
Minority Interest Rs m-1721,181 -14.5%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-170,718 0.0%   
Tax Rs m5,695-3,175 -179.4%   
Profit after tax Rs m14,92493,703 15.9%  
Gross profit margin %19.427.4 70.8%  
Effective tax rate %27.4-1.2 -2,243.6%   
Net profit margin %9.36.2 149.6%  
BALANCE SHEET DATA
Current assets Rs m124,2661,013,085 12.3%   
Current liabilities Rs m37,715883,496 4.3%   
Net working cap to sales %54.28.6 627.3%  
Current ratio x3.31.1 287.3%  
Inventory Days Days9191 99.8%  
Debtors Days Days9596 98.9%  
Net fixed assets Rs m105,190489,928 21.5%   
Share capital Rs m1,6113,692 43.6%   
"Free" reserves Rs m148,5110-   
Net worth Rs m150,1231,666,200 9.0%   
Long term debt Rs m38,301766,976 5.0%   
Total assets Rs m239,6333,427,948 7.0%  
Interest coverage x13.39.8 135.8%   
Debt to equity ratio x0.30.5 55.4%  
Sales to assets ratio x0.70.4 152.3%   
Return on assets %6.93.6 192.9%  
Return on equity %9.95.6 176.8%  
Return on capital %11.84.9 240.0%  
Exports to sales %34.70-   
Imports to sales %00-   
Net fx Rs m38,3680-   
CASH FLOW
From Operations Rs m16,911239,020 7.1%  
From Investments Rs m-16,687-84,694 19.7%  
From Financial Activity Rs m-3,487-286,721 1.2%  
Net Cashflow Rs m-3,451-132,395 2.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.84 Rs / USD

Compare CIPLA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare CIPLA With: ALEMBIC  UNICHEM LAB  STRIDES PHARMA SCIENCE  WYETH  FRESENIUS KABI ONCO.  



Today's Market

Sensex Ends 127 Points Higher; Auto Stocks Witness Huge Buying(Closing)

Share markets in India continued to trade on a positive note during closing hours today and ended their session marginally higher.

Related Views On News

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

My View on ITC (Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

The 'Seedhi Baat, No Bakwaas' View on ITC (Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

Why ITC and not HUL is my Idea of a Good Investment Right Now Views On News (Views On News)

Oct 15, 2020

Rahul Shah discusses HUL's lost decade and its implications for ITC.

Why India's Drone Revolution is a 4x Profit Opportunity (Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More
-->

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

CIPLA SHARE PRICE


Oct 23, 2020 (Close)

TRACK CIPLA

MORE ON CIPLA

CIPLA - SUN PHARMA COMPARISON

COMPARE CIPLA WITH

FEATURED VIDEOS

Value Vs Growth Investing: And the Winner Is...

Why ITC and not HUL is my Idea of a Good Investment Right Now

Contrarian Trading in PSU Banks

Why I Asked My Subscribers to Sell Stocks and Move into Cash?

More Featured Videos

MARKET STATS